GlassScriptPhysician profile
Baldwin S Stutts
NPI 1568561025
$6,140.15
in general payments reported to CMS, 2019-2025
31 companies · $678 in 2025
The $678 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $281 · 2021: $511 · 2022: $1,078 · 2023: $843 · 2024: $2,553 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,897 · Travel and Lodging: $1,167 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,897.28 |
| Travel and Lodging | $1,166.76 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,920.80 | 2021-2025 | Verquvo, Capvaxive, Steglatro |
| Abbott Laboratories | $1,276.00 | 2019-2025 | Assurity, Jot Dx, Merlin@Home |
| Novartis Pharmaceuticals Corporation | $762.53 | 2019-2025 | |
| Pfizer INC. | $568.98 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $189.01 | 2019-2024 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $174.44 | 2021-2023 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $148.81 | 2023-2024 | Inpefa |
| Amgen INC. | $139.35 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $106.44 | 2022-2025 | Eliquis, Orencia |
| Siemens Medical Solutions USA, INC. | $98.87 | 2025 | Acuson Origin Diagnostic Ultrasound System, Artis Icono Floor |
| Medtronic Vascular, INC. | $87.09 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.55 | 2022-2025 | |
| Novo Nordisk INC | $75.68 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| United Therapeutics Corporation | $58.77 | 2023-2024 | Tyvaso |
| Celgene Corporation | $47.71 | 2023-2024 | Orencia, Zeposia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $47.70 | 2022-2023 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.01 | 2023-2025 | Lifevest |
| Xeris Pharmaceuticals, INC. | $39.26 | 2025 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $37.98 | 2022 | |
| Inspire Medical Systems, INC. | $29.56 | 2023 | Inspire |
| Irhythm Technologies, INC. | $28.91 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $28.08 | 2023 | Arcalyst |
| Philips North America LLC | $20.05 | 2025 | Mcot |
| Zoll Medical Corporation | $20.03 | 2019 | |
| Bridgebio Pharma, INC. | $17.18 | 2025 | Attruby |
| Janssen Biotech, INC. | $17.17 | 2025 | Erleada, Akeega, Balversa |
| Edwards Lifesciences Corporation | $16.92 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 | |
| Boston Scientific Corporation | $13.05 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.83 | 2022 | |
| Bardy Diagnostics, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baldwin Stutts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.